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Abstract
Background: The aim of this study was to collect information about 2011 genetic activities in Italy, with the purpose
of providing guidance to the national health systems in order to improve genetic services.
Methods: A web-based survey was carried out to achieve the information.
Results: Data were collected from 268 macrostructures hosting 517 services and employing 3246 persons. About 295,000
cytogenetic, 35,000 immunogenetic and 263,000 molecular genetic analyses of 902 genes were recorded. Seventy-four
percent of the services were accredited with institutional bodies and 57 % were also certified according to ISO 9001
standard. Twenty percent of cytogenetic laboratories had participated in an European External Quality Assessment (EQA)
while 44 % participated in a national EQA. Only 28 % of the molecular laboratories had participated in a national Cystic
Fibrosis EQA. The percentage of diagnoses confirmed by genetic tests varied among disorders, ranging from 52 % for
coeliac disease to 4 % for fragile X syndrome.
Conclusions: This study highlights the need for reorganizing the Italian genetic services network, improving EQA
participation and developing national plans for implementing next generation technologies. Concerted effort has
to be addressed in the education of the professionals prescribing tests to improve appropriateness and to inform
patients, who now have exposure to direct-to-consumer multifactorial genetic testing where clinical utility is unproven.
Background
The Italian Society of Human Genetics (SIGU) launched
in 2012 a survey designed to scrutinize the 2011 activities
of the Italian Medical Genetic Services, to compare the
results with previous data collections, and to update the
national scenario. SIGU had previously carried out six sur-
veys to gather information on cytogenetic and molecular
testing and clinical genetics activities, with the aim of
providing guidance to the national and regional health sys-
tems to improve the organization of genetic services [1, 2].
Here, we report the results of this last study, providing
an overview of the changes occurred over a 4-year period,
highlighting the need for reviewing and improving the
Italian genetic structure network, in line with the current
public health requirements.
Methods
The survey refers to the medical genetic activities per-
formed in Italy from January 1st to December 31st, 2011.
This study was carried out by the Bambino Gesù Chil-
dren Hospital in Rome, in collaboration with Orphanet-
Italy, on behalf of SIGU. Ethical approval for this study
was granted by SIGU. Data were gathered by an ad hoc
questionnaire (http://docs.biomedia.net/SIGU/Schema-
Censimento_SIGU-2011.pdf ) sent to genetic centers
hosted by universities, research hospitals (Istituti di
Ricovero e Cura a Carattere Scientifico - IRCCS), general
hospitals, local health centers (Aziende Sanitarie Locali -
ASLs) and commercial laboratories. The enrolled genetic
centers were those registered and updated from the 2007
survey, integrated with others recruited through Orphanet
database (www.orpha.net) or joining voluntarily to this
initiative after learning of it during national scientific con-
ferences or through the SIGU website (www.sigu.net). A
verbal informed consent was obtained from participants.
Questions from previous surveys were reiterated
and new ones added, in order to achieve information
on the activities of immunogenetic laboratories and
diagnostic tests becoming available in more recent
years (i.e. microarrays). Entered data were based on self-
certification. Information was collected online from March
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to July 2012, using forms available in a dedicated website.
Each participating center accessed the website through a
private username and password assigned during the regis-
tration process. Requested data included total number and
type of performed cytogenetic and molecular genetic tests,
clinical genetic activities such as the number and type of
genetic counseling sessions. Data concerning the personnel
attending laboratories and clinical activities were also col-
lected. The quality management system of the responding
centers in terms of national accreditation standards and
international certifications was investigated, together with
national and international External Quality Assessment
enrolment. By comparing the number of analyses with
the number of diagnoses confirmed by the test results,
appropriateness was evaluated for the following entities:
achondroplasia, Angelman, DiGeorge, fragile X-mental
retardation, Noonan, Prader-Willi and Williams syndromes,
ankylosing spondylitis and coeliac diseases. Appropriateness
was investigated also for CGH (Comparative Genomic




Overall, 268 genetic centers, hosting 517 genetic services
(genetic testing and counselling) were surveyed (Table 1).
25 % of these services were located in public hospitals,
21 % in university hospitals, 21 % in IRCCS, 16 % in pri-
vate centers, 9 % in ASLs, 5 % in universities, and 4 % in
a different institution (Fig. 1). The genetic units included
145 clinical services and 372 diagnostic laboratories,
comprising 153 cytogenetic, 198 molecular, and 21 immu-
nogenetic laboratories (Table 1). By comparing the num-
ber of the 2011 censused structures with the previous two
surveys, an increase of clinical genetic services appeared
evident with a slight decrease in the cytogenetic and mo-
lecular genetic laboratories (Fig. 2). The collected data was
representative of the genetic services in Italy as a whole. A
decreasing gradient of the total number of genetic centers
from North to South and to the Islands of Italy was ob-
served in previous studies and was substantiated in the
present analysis (Table 1). A total of 3246 persons were
employed in the national genetic services, of which 38 %
biologists, 21 % technicians, 16 % medical doctors, 6 %
biotechnologists, 1 % bioinformaticians, 1 % graduated in
different disciplines, 7 % healthcare personnel, 9 % admin-
istrative, and 2 % other staff (Fig. 3). Centers that had
adopted a Quality Management System are shown in
Table 2: 74 % of the services were institutionally accre-
dited by regional bodies. In addition to this institutional
accreditation, 57 % of services were also voluntarily certi-
fied according to ISO (International Organization for
Standardization) 9001 standard, 7 % accredited accord-
ing to ISO 15189, about 5 % to SIGU and 4 % to JCI
(Joint Commission International) standards. Seven out
of 21 immunogenetic laboratories had obtained the EFI
(European Federation for Immunogenetics) accreditation.
Cytogenetic laboratories and activity
Forty-six percent of cytogenetic laboratories were lo-
cated in the Northern regions, compared with 21 % in
Central regions, 20 % in Southern regions, and 11 % in
the Islands (Table 1). The total number of cytogenetic
laboratories had decreased slightly compared to 2007
(Fig. 2), and the total number of analyses dropped from
312,881 in 2007 to 294,155 in 2011 (Table 3). This dim-
inution occurred in both the constitutional prenatal and
postnatal tests, and this decrease may be a consequence
of their replacement by the molecular tests. For example,
in 2011 a total of 19,908 QF-PCR (Quantitative Fluores-
cent- Polymerase Chain Reaction) were performed (the
2007 figure is not available) negating the need for full
chromosome analysis in some cases. In addition, 1862
prenatal microarray tests were undertaken (compared to
393 in 2007).
Cancer cytogenetic tests increased from 2000 onwards
with the greater contribution for this escalation being
attributable to an increase of FISH (Fluorescent In Situ
Hybridization) and ISH (In Situ Hybridization) analyses.
One aspect of a Quality Management System is the
participation in an accredited external quality assessment
(EQA) scheme. Only 30 of 153 censused laboratories
(20 %) had taken part in an international accredited
Cytogenetic European Quality Assessment (CEQA, now
Table 1 Geographical distribution of the censused structures
Area Medical % Genetic services
genetic centers CL % MGL % IGL % CGS % Total
Northern 142 53 70 46 101 51 8 38 68 47 247
Central 54 20 32 21 45 23 7 33 34 23 118
Southern 45 17 31 20 34 17 5 24 30 21 100
Islander 27 10 20 13 18 9 1 5 13 9 52
Total 268 153 198 21 145 517
CL Cytogenetic Laboratories, MGL Molecular Genetic Laboratories, IGL Immunogenetic Laboratories, CGS Clinical Genetic Services, %, % of structures located in a
specific geographic area out of the total of the censused structures
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known as CEQAS) (Fig. 4) and 68 (44 %) in the national
cytogenetic EQA scheme (personal communication
provided by Italian National Centre for rare Diseases –
Istituto Superiore di Sanità, Rome, Italy). Figure 4 also
shows that the number of laboratories that effectively
participated (enrolled) in an international QA (Quality
Assessment) is lower than that registered to attend.
Molecular genetic laboratories and activity
Fifty-one percent of 198 molecular genetic laboratories
were located in Northern regions, 23 % in Central re-
gions, 17 % in Southern regions, and 9 % in the Islands
(Table 1). The number of surveyed molecular analyses
(263,246) increased by 6 %, compared to the 2007 study
(248,691) (Fig. 5). The total number of analyzed genes
was 902 (Table 4), a figure consistently higher compared
with previous 2007 report (556), which is starting to
bridge the previous gap between the number of analyzed
genes and the number of disease genes amenable for in-
vestigation [3]. Seventy percent of the molecular tests
(184,679 of 263,246 analyses) included 15 disease genes
or group of genes, the analysis of CFTR gene accounting
for 21 % of total (Table 5). Tests of susceptibility to com-
mon diseases comprised about 64,000 tests (24 % of the
total), mainly exploring genes within the thrombophilia
cascade and about 18,000 analyses (6 %) of the major
histocompatibility complex (HLA), primarily for disease
association studies (Table 5). In the 2007 survey, the sus-
ceptibility tests accounted for about 37 % of all molecu-
lar analyses.
Only 55 of 198 molecular genetic laboratories (28 %)
participated in either a national or international cystic
fibrosis EQA schemes. It is likely that not all the 198
censused laboratories offered genetic testing for cystic
fibrosis, but the majority did, although the participation
in EQA was lower than desirable.
A total of 35,446 molecular genetic analyses had been
performed by 21 immunogenetic laboratories in 2011,
indicating a sharp and constant increase during the last
12 years (Fig. 6).
Fig. 1 Distribution by affiliation of the 517 services performing genetic activities during 2011 in Italy
Fig. 2 Number of censused structures in the SIGU surveys of 2004, 2007 and 2011
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Clinical genetic services and activity
Forty-seven percent of 145 clinical genetic services were
located in Northern regions, 23 % in Central regions,
and 21 % in Southern/Island regions (Table 1). A total of
100,001 genetic counseling sessions were performed in
2011, mainly for single gene diseases (20 %), chromo-
some anomalies detected at prenatal or postnatal testing
(15 %), infertility (12 %), cancer (11 %), dysmorphic syn-
dromes (11 %), and intellectual disability disorders (7 %)
(Table 6). The 2004–2011 trend of genetic counseling
activity is shown in Fig. 7. The total number of regis-
tered genetic counseling sessions with respect to the
laboratory diagnostic activities was quite low, only 12 %
(11 % in 2007) of all genetic analyses had been accom-
panied by pre-test or post-test counseling.
Appropriateness of the tests
The appropriateness of genetic testing was assessed by
investigating the congruence between the clinical diag-
nosis and the test results in nine disorders (Table 7),
selected on the basis of their easily recognizable clinical
phenotype and the significant number of evaluated cases.
Clinical diagnosis was substantiated in 52 % of patients
with celiac disease, 15 % with ankylosing spondylitis,
23 % with Williams syndrome (3 % in 2007), 33 % with
DiGeorge/Velocardiofacial syndrome (3 % in 2007), 4 %
with fragile-X syndrome, 7 % with Angelman syndrome
(9 % in 2007), 8 % with Prader-Willi syndrome (18 % in
2007), and 45 % with achondroplasia (36 % in 2007).
Worthy of note was the 4 % figure of the confirmed
fragile X syndrome cases. Fifteen percent of CGH-array
analyses (1383 out of 9355 tests) disclosed pathogenic
Copy Number Variations (CNVs), including 407 dele-
tions resulting in known deletion syndromes.
Discussion
The survey of the Italian medical genetic centers in year
2011 was carried out on the behalf of SIGU. This study
aimed at providing indications to the national and
regional public health systems, in agreement with the
Regional Health System request to rationalize and inte-
grate the public genetic laboratories under the pressure
of the spending review and the need to improve effi-
ciency. Indeed, the national health system is fully sup-
porting the cost of genetic testing requested by the
specialists, with some limitations for prenatal testing in
women under the age of 35 years and/or without any
specific indication. Accordingly to previous reviews, the
number of genetic services was exceeding that required
against the approximately 60,000,000 total inhabitants.
Indeed the Minister of Health and the Italian Regions
suggested that the maximums should be 1,000,000 in-
habitants for every clinical genetics facility between
500,000 and 1,000,000 inhabitants for every cytogenetic
Fig. 3 Professional qualifications of the staff employed in the Italian genetic services



















Northern 109 83 13 0 7 4 1 9
Central 42 31 7 1 1 2 0 3
Southern 28 22 0 1 2 0 0 0
Islander 19 17 0 0 0 1 0 1
Totala 198 153 20 2 10 7 1 13
%b 73,8 57,1 7,4 0,7 3,7 2,6 0,3 4,8
aTotal number of accredited/certified structures
b% of accredited-certified centers out of the total of the censused centers
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Table 3 Constitutional and oncological cytogenetic analyses surveyed by SIGU since 2000
Year
Type of tissue/analysis 2000 2002 2004 2007 2011
Prenatal cytogenetic tests Number
Amniotic Fluid 77395 95729 101011 101750 97320
Chorionic villi 9169 15159 18357 25691 25520
Fetal blood 784 808 870 478 383
Spontaneous abortions 2874 5231 6483 8415 5856
Prenatal FISH 8643 20032 26331 2891a
Rapid FISH for aneuploidies 4288
Microarray (CGH and SNPs) 393 1862
Total Prenatal tests 90222 125570 146753 163058 138120
Postnatal cytogenetic tests
Peripheral blood 65148 81153 8,478 69841
Fibroblasts 493 1258 1184 811
Other 213 502
Postnatal FISH 4776 22999 22653 5819b
Microarray (CGH and SNPs) 1443 8290
Total Postnatal tests 49696 70630 105410 108758 85263
Oncological cytogenetic tests
Bone marrow 23445 27323 34500 31538
Peripheral blood 2873
Solid tumors 1671 2482
Metaphase ish 8383 4112 6565 4142
Interphase ish 27821
Microarray (CGH and SNPs) 1916
Total oncological cytogenetic tests 15948 33499 31435 41065 70772
TOTAL CYTOGENETIC TESTS 155866 229699 283598 312881 294155
aFISH for microdeletion syndromes (897), subtelomeric regions (276), extra structurally abnormal chromosomes (599) and rearrangement (1119) characterization.
bFISH for microdeletion syndromes (2662), subtelomeric regions (1186), extra structurally abnormal chromosomes (455) and rearrangement (1516) characterization
Fig. 4 CEQA Registration vs Enrolment (effective participation) of Italian Cytogenetic Laboratories during the last years
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laboratory and not less than 3,000,000 inhabitants for
every molecular genetic laboratory (http://www.salute.
gov.it/imgs/c_17_pubblicazioni_908_allegato.pdf ). The
total number of genetic services in Table 1 clearly at-
tests an oversize in all kinds of services.
As shown in this report, the coverage of the Italian
territory by genetic testing facilities is one of the highest
in Europe. In addition there is not equal distribution of
the genetic services across the country, mainly attribut-
able to economic reasons, since both public and private
genetic services initially began in the rich regions of
Northern Italy, which also are the most densely inhab-
ited [2]. To date, only a few Italian regions have imple-
mented strategic plans for reducing the number of
centers through a coordination of their activities [4].
The SIGU 2011 survey evidenced a slightly lower
number of genetic services compared to the 2007 data
and confirmed that more than 50 % of all genetic ser-
vices were located in Northern regions. A total of 3246
health professionals worked in these services, 44 % of
which were biologists or biotechnologists as compared
to only 21 % of technicians, an Italian anomaly contrast-
ing the trend observed in other European countries and
mainly attributable to the availability of the former to
accept scholarships.
In the last decade guidelines regulating the activities of
clinical and laboratory genetic services were jointly
developed by the Ministry of Health and the Italian
Regions, establishing roles and functions of genetic ser-
vices [1]. According to National and Regional Health
System, public Medical Genetics Services must operate
within a Quality Management System, accredited by in-
stitutional bodies. Quality is defined by a number of re-
quirements, which are not limited to organizational,
professional, technical, procedural and communication
elements. A significant improvement in the adoption of
Quality Management Systems was registered in 2011,
with respect to 2007. Indeed, 74 % of genetics structures
turned out to be institutionally accredited, 57 % to be
also voluntarily certified according to ISO 9001 standard
(28 % in 2007) and a few voluntarily accredited accord-
ing to ISO 15189. About 5 % of genetic services volun-
tarily accredited according to the quality standard for
genetic structures elaborated by SIGU (www.sigu.net).
The Italian state of quality systems within genetic testing
services is similar to the European overview provided by
Berwouts et al. [5]. Again, a North to South gradient
was registered, with the majority of the accredited/certi-
fied services being located in Northern regions.
Collected data, showed that only 20 % of cytogenetic
laboratories participated in the accredited CEQAS
(formerly CEQA) and 44 % in the Istituto Superiore di
Sanità (ISS, EQA national provider) schemes. Only a
minority of the molecular laboratories stated they par-
ticipated in an EQA scheme for cystic fibrosis. The par-
ticipation in EQA is an established tool for improving
quality, educating laboratory staff and directing labora-
tories towards best practices. National rules establish
that medical laboratories shall participate in EQA
scheme in order to be institutionally accredited, but
appropriate checks to verify the participation of the
genetic laboratories in EQA are only occasionally car-
ried out by responsible bodies.
Fig. 5 Molecular genetics analyses surveyed by SIGU since 1997




Genes tested in Europe
(source: Orphanet/EurogenTest)
1500 1812 2179
Genes tested in Italy
(source: SIGU survey)
556 (37 %) 902 (50 %) 1042 (48 %)
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As shown in this report, the coverage of the Italian
territory by genetic testing facilities is one of the highest
in Europe. Table 4 shows that the 50 % of genetic tests
available in Europe at time of survey were available also
in Italy (902 genes investigated in 2011 compared to the
556 disease genes in 2007). Data collected by Orphanet-
Italy referring to year 2012 figure showed an additional
increase, with 1107 investigated disease genes. This posi-
tive trend places Italy at the fourth position in Europe,
after Germany, Spain, and France [3]. In the case of tests
not available in Italy, disease-gene analysis is performed
using cross-border facilities. According to the Kääriäinen
European survey [6] including also data from Italy, about
the 3 % of genetic analyses in Europe are performed
cross-border.
The need for a revision of the national molecular diag-
nostic network and for a diversification of the offer are
supported by the results of the present survey, showing
that testing of 15 disease-genes only accounted for 70 %
of all molecular analyses in 2011. In addition, the demand
of molecular tests has increased by a figure of 20 % from
2007 onwards, and cytogenetic analyses has reached a
plateau of around 300,000 tests per year. Compared with
the results registered by the 2007 census, the request of
molecularly testing the susceptibility to common disorders
and complex phenotypes was not increased, the analysis
of thrombophilia cascade genes and HLA accounting for
about 30 % of all molecular tests.
The request of constitutional prenatal and postnatal
chromosome analyses has decreased in recent years. In
particular, the number of genetic tests in amniocytes,
which had been stable between 2004–2007, decreased in
the years preceding the present survey, while the num-
ber of test on chorionic villi, increased by about 2500
per year in 2007–2011, stabilizing at around 25,500. It is
expected that the decreasing trend of invasive prenatal
tests will be further corroborated in the coming years,
due to introduction of Non-Invasive Prenatal Testing
(NIPT) into the diagnostic set.
The reduction of constitutional postnatal cytogenetic
tests appears mainly related to the decrease of FISH ana-
lyses, which was expanded in the early 2000s, in parallel
with the increased availability of commercial probes test-
ing for cryptic deletions and supernumerary markers. A
similar trend was also seen prenatally, with a consistent
decrease of FISH tests. Between 2007–2011, FISH analyses
had been progressively substituted by microarrays testing,
as shown by the 8290 postnatal and 1862 prenatal tests
(18 % of the total) in 2011, compared to 1443 and 393
respectively in 2007. The reduction in FISH prenatal tests
was related also to the widespread use of QF-PCR for
detecting major aneuploidies.
By contrast, oncological cytogenetic tests had in-
creased by 58 %, mainly as a consequence of the wider
introduction of FISH interphase analysis in genetic cen-
ters as documented by Table 3. One possible reason is
the adoption of interphase FISH for detecting cryptic
chromosome rearrangements in neoplastic disorders as
recommended by the international guidelines.
As to previous concerns on the appropriateness of
genetic testing requested by referring clinical geneticists,
the 2011 results show an increase in the confirmed
diagnoses for DiGeorge/Velocardiofacial and Williams
syndromes, and a significant decrease for Prader-Willi
syndrome compared to 2007 (see Table 7).
Only 12 % of all genetic analyses were accompanied by
genetic counseling, in contrast with international [7] and
national recommendations [8, 9]. Inappropriate replace-
ment of the patient communication session by professionals
Table 5 Top 15 molecular genetic tests in Italy, year 2011
Number Percent
Cystic fibrosis (CFTR) 55716 21
Factor V Leiden mutation (F5) 24834 9
Coagulation Factor II mutation (F2) 20393 8
MTHFR Deficit 18526 7
Celiac Disease (HLA) 11824 4
Beta thalassemia (HBB) 7796 3
Fragile X syndrome (FRAXA) 7695 3
Chronic Myeloid Leukaemia (BCR/ABL) 7131 3
Rheumatic Diseases (HLA) 6431 2
Hemochromatosis (HFE) 5088 2
Neurosensory deafness (GJB6) 4895 2
Duchenne/Becker muscular dystrophy (DMD) 3823 1
Breast cancer (BRCA1/2) 3821 1
Acute Myeloid Leukaemia 3579 1
Y chromosome microdeletion (AZF) 3127 1
Total 184679 70
Fig. 6 Increase of immunogenetic analyses in Italy since 2004
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of contiguous fields could account for the poor detection
rate in these syndromes.
Since 2011 no substantial changes have been intro-
duced in the Italian public genetic diagnostic field. In
fact, the more recently developed tests (NGS: Next
Generation Sequencing; NIPT) have not yet entered in
the diagnostics setting and remain restricted to a re-
search application. Public healthcare in Italy is now ad-
ministrated on a regional basis and a concerted effort
must be made to review and rationalize the network of
genetic services nationally, taking into account the re-
sults of this present survey. In fact, this study provides a
real and detailed representation about the logistic of the
genetic centers, the number of performed genetic tests,
the quality of provided services, the appropriateness of
genetic test requests and the number of employees.
Within this setting, a number of recommendations can
be given for improving genetic services in Italy, which is
at present oversized and nonharmonious. Some priority
issues are emerging, including management of quality
systems in terms of accreditation, certification, and EQA
participations; accessibility of pre-test and post-test
genetic counseling; the need of increasing availability of
genetic testing for rare diseases; the development of
national plans and strategies for implementing next
generation technologies and advising on the clinical util-
ity of genetic testing for complex disorders. The quality
standard for genetic structures elaborated by SIGU may
be adopted by a national competent body responsible for
the specific accreditation and quality assurance of the
genetic services. Another challenge, focused by Battista
et al. [4], refers to the need of reconfiguring the profes-
sional roles and responsibilities. An additional effort
concerns the education and training of those prescribing
genetic tests, which should be utilized as a valuable
support to good clinical practice and evidence based
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Fig. 7 2004-2011 trend in demand for genetic counseling in Italy
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medicine. A parallel commitment must be to inform
citizens, nowadays exposed to an ever more present and
available direct-to-consumergenetic testing which has
little proven clinical utility.
Conclusions
This study provides a real and detailed representation
about the logistics of the genetic centers operating in
Italy, the quality of their provided services, the number
of performed genetic tests, and the number of em-
ployees. There are too many genetic services given the
population size of Italy and they are not equally dis-
tributed across the country. Quality assurance of the
genetic services may be improved through a specific
accreditation standard. Good clinical practice and evi-
dence based medicine may be implemented through
the education and training of the people involved in
the prescriptions of genetic tests. The finding that
70 % of all molecular analyses performed in 2011 was
related to only 15 disease-genes, strongly supports the
need for a revision of the national molecular diagnostic
network. All together, these results provide informa-
tion useful for improving genetic services in Italy.
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